Active Pharmaceutical Ingredients - Global Market Outlook (2016-2022)

  • ID: 4335745
  • Report
  • Region: Global
  • Stratistics Market Research Consulting Pvt Ltd
1 of 4

FEATURED COMPANIES

  • Aurobindo Pharma Ltd.
  • Ceva Animal Health, Inc.
  • Heska Co. (U.S.)
  • Novartis International AG
  • Pfizer, Inc
  • Ranbaxy Laboratories
  • MORE

The Global Active Pharmaceutical Ingredients market is expected to reach $198.8 billion by 2022 with a CAGR of 6.4%. Patent expiration of prominent drugs, government initiatives, regional penetration and increasing aged population are some of the factors that are driving the market growth. Strict validation and safety guidelines stated by WHO and fragmented market are the factors that are hampering the API market growth.

Generic/Non- Branded segment witnessed the largest market share during the forecast period due to rising healthcare costs, government prominence on generics for dropping healthcare costs, and decreasing pipelines of global pharmaceutical products. Asia Pacific is expected to be highest market share during the forecast period due to low operation costs and high investments in medical research. Moreover, the high cost of skilled labour and energy are the most significant factors that enforced European market to move its base to developing countries, such as India and China.

Some of the key players in global Active Pharmaceutical Ingredients market include Bioniche Animal Health (Canada), Boehringer Ingelheim (Germany), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Bayer Healthcare (Germany), Merial Inc. (Sanofi) (France), Elanco Animal Health (U.S.), Merck Animal Health (U.S.), Ceva Animal Health, Inc., Dr. Reddy’s Laboratories Ltd., Novartis International AG, Ranbaxy Laboratories, Virbac, Zoetis (U.S.), Pfizer, Inc, Aurobindo Pharma Ltd., and Heska Co. (U.S.).

Types of API Covered:

  • Synthetic chemical API
    • Branded/ Innovative
    • Generic/Non- Branded
  • Biological API
    • Biotech
    • Biosimilar
  • High potency active pharmaceutical ingredients(HPAPI)

Manufacturing Types Covered:

  • Captive (or in-house) manufacturing
  • Contract manufacturing

Therapeutic Applications Covered:

  • Anti-Infectives
  • Cardiovascular and hematopoietic system
  • CNS and Neurological Disorders
  • Diabetes
  • Endocrinology
  • Gastrointestinal disorder
  • Hormonal-related disorder
  • Metabolic disorder
  • Musculoskeletal disorder
  • Nephrology
  • Oncology
  • Ophthalmology
  • Orthopedic Disorders
  • Pulmonology

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • Rest of the World
    • Middle East
    • Brazil
    • Argentina
    • South Africa
    • Egypt

What our report offers:

  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aurobindo Pharma Ltd.
  • Ceva Animal Health, Inc.
  • Heska Co. (U.S.)
  • Novartis International AG
  • Pfizer, Inc
  • Ranbaxy Laboratories
  • MORE

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Emerging Markets
3.8 Futuristic Market Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Active Pharmaceutical Ingredients Market, By Types of API
5.1 Introduction
5.2 Synthetic chemical API
5.2.1 Branded/ Innovative
5.2.2 Generic/Non- Branded
5.3 Biological API
5.3.1 Biotech
5.3.2 Biosimilar
5.4 High potency active pharmaceutical ingredients(HPAPI)

6 Global Active Pharmaceutical Ingredients Market, By Type of Manufacturing
6.1 Introduction
6.2 Captive (or in-house) manufacturing
6.3 Contract manufacturing

7 Global Active Pharmaceutical Ingredients Market, By Therapeutic Application
7.1 Introduction
7.2 Anti-Infectives
7.3 Cardiovascular and hematopoietic system
7.4 CNS and Neurological Disorders
7.5 Diabetes
7.6 Endocrinology
7.7 Gastrointestinal disorder
7.8 Hormonal-related disorder
7.9 Metabolic disorder
7.10 Musculoskeletal disorder
7.11 Nephrology
7.12 Oncology
7.13 Ophthalmology
7.14 Orthopedic Disorders
7.15 Pulmonology

8 Global Active Pharmaceutical Ingredients Market, By Geography
8.1 North America
8.1.1 US
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 France
8.2.3 Italy
8.2.4 UK
8.2.5 Spain
8.2.6 Rest of Europe
8.3 Asia Pacific
8.3.1 Japan
8.3.2 China
8.3.3 India
8.3.4 Australia
8.3.5 New Zealand
8.3.6 Rest of Asia Pacific
8.4 Rest of the World
8.4.1 Middle East
8.4.2 Brazil
8.4.3 Argentina
8.4.4 South Africa
8.4.5 Egypt

9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling
10.1 Bioniche Animal Health (Canada)
10.2 Boehringer Ingelheim (Germany)
10.3 Sun Pharmaceutical Industries Ltd.
10.4 Teva Pharmaceutical Industries Limited
10.5 Bayer Healthcare (Germany)
10.6 Merial Inc. (Sanofi) (France)
10.7 Elanco Animal Health (U.S.)
10.8 Merck Animal Health (U.S.)
10.9 Ceva Animal Health, Inc.
10.10 Dr. Reddy’s Laboratories Ltd.
10.11 Novartis International AG
10.12 Ranbaxy Laboratories
10.13 Virbac
10.14 Zoetis (U.S.)
10.15 Pfizer, Inc
10.16 Aurobindo Pharma Ltd.
10.17 Heska Co. (U.S.)

List of Tables
1 Global Active Pharmaceutical Ingredients Market Outlook, By Region (2013-2022) ($MN)
2 Global Active Pharmaceutical Ingredients Market Outlook, By Types of API (2013-2022) ($MN)
3 Global Active Pharmaceutical Ingredients Market Outlook, By Synthetic chemical API (2013-2022) ($MN)
4 Global Active Pharmaceutical Ingredients Market Outlook, By Branded/ Innovative (2013-2022) ($MN)
5 Global Active Pharmaceutical Ingredients Market Outlook, By Generic/Non- Branded (2013-2022) ($MN)
6 Global Active Pharmaceutical Ingredients Market Outlook, By Biological API (2013-2022) ($MN)
7 Global Active Pharmaceutical Ingredients Market Outlook, By Biotech (2013-2022) ($MN)
8 Global Active Pharmaceutical Ingredients Market Outlook, By Biosimilar (2013-2022) ($MN)
9 Global Active Pharmaceutical Ingredients Market Outlook, By High potency active pharmaceutical ingredients(HPAPI) (2013-2022) ($MN)
10 Global Active Pharmaceutical Ingredients Market Outlook, By Type of manufacturing (2013-2022) ($MN)
11 Global Active Pharmaceutical Ingredients Market Outlook, By Captive (or in-house) manufacturing (2013-2022) ($MN)
12 Global Active Pharmaceutical Ingredients Market Outlook, By Contract manufacturing (2013-2022) ($MN)
13 Global Active Pharmaceutical Ingredients Market Outlook, By Therapeutic applications (2013-2022) ($MN)
14 Global Active Pharmaceutical Ingredients Market Outlook, By Anti-Infectives (2013-2022) ($MN)
15 Global Active Pharmaceutical Ingredients Market Outlook, By Cardiovascular and hematopoietic system (2013-2022) ($MN)
16 Global Active Pharmaceutical Ingredients Market Outlook, By CNS and Neurological Disorders (2013-2022) ($MN)
17 Global Active Pharmaceutical Ingredients Market Outlook, By Diabetes (2013-2022) ($MN)
18 Global Active Pharmaceutical Ingredients Market Outlook, By Endocrinology (2013-2022) ($MN)
19 Global Active Pharmaceutical Ingredients Market Outlook, By Gastrointestinal disorder (2013-2022) ($MN)
20 Global Active Pharmaceutical Ingredients Market Outlook, By Hormonal-related disorder (2013-2022) ($MN)
21 Global Active Pharmaceutical Ingredients Market Outlook, By Metabolic disorder (2013-2022) ($MN)
22 Global Active Pharmaceutical Ingredients Market Outlook, By Musculoskeletal disorder (2013-2022) ($MN)
23 Global Active Pharmaceutical Ingredients Market Outlook, By Nephrology (2013-2022) ($MN)
24 Global Active Pharmaceutical Ingredients Market Outlook, By Oncology (2013-2022) ($MN)
25 Global Active Pharmaceutical Ingredients Market Outlook, By Ophthalmology (2013-2022) ($MN)
26 Global Active Pharmaceutical Ingredients Market Outlook, By Orthopedic Disorders (2013-2022) ($MN)
27 Global Active Pharmaceutical Ingredients Market Outlook, By Pulmonology (2013-2022) ($MN)
28 North America Active Pharmaceutical Ingredients Market Outlook, By Country (2013-2022) ($MN)
29 North America Active Pharmaceutical Ingredients Market Outlook, By Types of API (2013-2022) ($MN)
30 North America Active Pharmaceutical Ingredients Market Outlook, By Synthetic chemical API (2013-2022) ($MN)
31 North America Active Pharmaceutical Ingredients Market Outlook, By Branded/ Innovative (2013-2022) ($MN)
32 North America Active Pharmaceutical Ingredients Market Outlook, By Generic/Non- Branded (2013-2022) ($MN)
33 North America Active Pharmaceutical Ingredients Market Outlook, By Biological API (2013-2022) ($MN)
34 North America Active Pharmaceutical Ingredients Market Outlook, By Biotech (2013-2022) ($MN)
35 North America Active Pharmaceutical Ingredients Market Outlook, By Biosimilar (2013-2022) ($MN)
36 North America Active Pharmaceutical Ingredients Market Outlook, By High potency active pharmaceutical ingredients(HPAPI) (2013-2022) ($MN)
37 North America Active Pharmaceutical Ingredients Market Outlook, By Type of manufacturing (2013-2022) ($MN)
38 North America Active Pharmaceutical Ingredients Market Outlook, By Captive (or in-house) manufacturing (2013-2022) ($MN)
39 North America Active Pharmaceutical Ingredients Market Outlook, By Contract manufacturing (2013-2022) ($MN)
40 North America Active Pharmaceutical Ingredients Market Outlook, By Therapeutic applications (2013-2022) ($MN)
41 North America Active Pharmaceutical Ingredients Market Outlook, By Anti-Infectives (2013-2022) ($MN)
42 North America Active Pharmaceutical Ingredients Market Outlook, By Cardiovascular and hematopoietic system (2013-2022) ($MN)
43 North America Active Pharmaceutical Ingredients Market Outlook, By CNS and Neurological Disorders (2013-2022) ($MN)
44 North America Active Pharmaceutical Ingredients Market Outlook, By Diabetes (2013-2022) ($MN)
45 North America Active Pharmaceutical Ingredients Market Outlook, By Endocrinology (2013-2022) ($MN)
46 North America Active Pharmaceutical Ingredients Market Outlook, By Gastrointestinal disorder (2013-2022) ($MN)
47 North America Active Pharmaceutical Ingredients Market Outlook, By Hormonal-related disorder (2013-2022) ($MN)
48 North America Active Pharmaceutical Ingredients Market Outlook, By Metabolic disorder (2013-2022) ($MN)
49 North America Active Pharmaceutical Ingredients Market Outlook, By Musculoskeletal disorder (2013-2022) ($MN)
50 North America Active Pharmaceutical Ingredients Market Outlook, By Nephrology (2013-2022) ($MN)
51 North America Active Pharmaceutical Ingredients Market Outlook, By Oncology (2013-2022) ($MN)
52 North America Active Pharmaceutical Ingredients Market Outlook, By Ophthalmology (2013-2022) ($MN)
53 North America Active Pharmaceutical Ingredients Market Outlook, By Orthopedic Disorders (2013-2022) ($MN)
54 North America Active Pharmaceutical Ingredients Market Outlook, By Pulmonology (2013-2022) ($MN)
55 Europe Active Pharmaceutical Ingredients Market Outlook, By Country (2013-2022) ($MN)
56 Europe Active Pharmaceutical Ingredients Market Outlook, By Types of API (2013-2022) ($MN)
57 Europe Active Pharmaceutical Ingredients Market Outlook, By Synthetic chemical API (2013-2022) ($MN)
58 Europe Active Pharmaceutical Ingredients Market Outlook, By Branded/ Innovative (2013-2022) ($MN)
59 Europe Active Pharmaceutical Ingredients Market Outlook, By Generic/Non- Branded (2013-2022) ($MN)
60 Europe Active Pharmaceutical Ingredients Market Outlook, By Biological API (2013-2022) ($MN)
61 Europe Active Pharmaceutical Ingredients Market Outlook, By Biotech (2013-2022) ($MN)
62 Europe Active Pharmaceutical Ingredients Market Outlook, By Biosimilar (2013-2022) ($MN)
63 Europe Active Pharmaceutical Ingredients Market Outlook, By High potency active pharmaceutical ingredients(HPAPI) (2013-2022) ($MN)
64 Europe Active Pharmaceutical Ingredients Market Outlook, By Type of manufacturing (2013-2022) ($MN)
65 Europe Active Pharmaceutical Ingredients Market Outlook, By Captive (or in-house) manufacturing (2013-2022) ($MN)
66 Europe Active Pharmaceutical Ingredients Market Outlook, By Contract manufacturing (2013-2022) ($MN)
67 Europe Active Pharmaceutical Ingredients Market Outlook, By Therapeutic applications (2013-2022) ($MN)
68 Europe Active Pharmaceutical Ingredients Market Outlook, By Anti-Infectives (2013-2022) ($MN)
69 Europe Active Pharmaceutical Ingredients Market Outlook, By Cardiovascular and hematopoietic system (2013-2022) ($MN)
70 Europe Active Pharmaceutical Ingredients Market Outlook, By CNS and Neurological Disorders (2013-2022) ($MN)
71 Europe Active Pharmaceutical Ingredients Market Outlook, By Diabetes (2013-2022) ($MN)
72 Europe Active Pharmaceutical Ingredients Market Outlook, By Endocrinology (2013-2022) ($MN)
73 Europe Active Pharmaceutical Ingredients Market Outlook, By Gastrointestinal disorder (2013-2022) ($MN)
74 Europe Active Pharmaceutical Ingredients Market Outlook, By Hormonal-related disorder (2013-2022) ($MN)
75 Europe Active Pharmaceutical Ingredients Market Outlook, By Metabolic disorder (2013-2022) ($MN)
76 Europe Active Pharmaceutical Ingredients Market Outlook, By Musculoskeletal disorder (2013-2022) ($MN)
77 Europe Active Pharmaceutical Ingredients Market Outlook, By Nephrology (2013-2022) ($MN)
78 Europe Active Pharmaceutical Ingredients Market Outlook, By Oncology (2013-2022) ($MN)
79 Europe Active Pharmaceutical Ingredients Market Outlook, By Ophthalmology (2013-2022) ($MN)
80 Europe Active Pharmaceutical Ingredients Market Outlook, By Orthopedic Disorders (2013-2022) ($MN)
81 Europe Active Pharmaceutical Ingredients Market Outlook, By Pulmonology (2013-2022) ($MN)
82 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Country (2013-2022) ($MN)
83 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Types of API (2013-2022) ($MN)
84 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Synthetic chemical API (2013-2022) ($MN)
85 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Branded/ Innovative (2013-2022) ($MN)
86 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Generic/Non- Branded (2013-2022) ($MN)
87 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Biological API (2013-2022) ($MN)
88 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Biotech (2013-2022) ($MN)
89 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Biosimilar (2013-2022) ($MN)
90 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By High potency active pharmaceutical ingredients(HPAPI) (2013-2022) ($MN)
91 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Type of manufacturing (2013-2022) ($MN)
92 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Captive (or in-house) manufacturing (2013-2022) ($MN)
93 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Contract manufacturing (2013-2022) ($MN)
94 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Therapeutic applications (2013-2022) ($MN)
95 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Anti-Infectives (2013-2022) ($MN)
96 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Cardiovascular and hematopoietic system (2013-2022) ($MN)
97 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By CNS and Neurological Disorders (2013-2022) ($MN)
98 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Diabetes (2013-2022) ($MN)
99 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Endocrinology (2013-2022) ($MN)
100 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Gastrointestinal disorder (2013-2022) ($MN)
101 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Hormonal-related disorder (2013-2022) ($MN)
102 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Metabolic disorder (2013-2022) ($MN)
103 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Musculoskeletal disorder (2013-2022) ($MN)
104 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Nephrology (2013-2022) ($MN)
105 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Oncology (2013-2022) ($MN)
106 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Ophthalmology (2013-2022) ($MN)
107 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Orthopedic Disorders (2013-2022) ($MN)
108 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Pulmonology (2013-2022) ($MN)
109 RoW Active Pharmaceutical Ingredients Market Outlook, By Country (2013-2022) ($MN)
110 RoW Active Pharmaceutical Ingredients Market Outlook, By Types of API (2013-2022) ($MN)
111 RoW Active Pharmaceutical Ingredients Market Outlook, By Synthetic chemical API (2013-2022) ($MN)
112 RoW Active Pharmaceutical Ingredients Market Outlook, By Branded/ Innovative (2013-2022) ($MN)
113 RoW Active Pharmaceutical Ingredients Market Outlook, By Generic/Non- Branded (2013-2022) ($MN)
114 RoW Active Pharmaceutical Ingredients Market Outlook, By Biological API (2013-2022) ($MN)
115 RoW Active Pharmaceutical Ingredients Market Outlook, By Biotech (2013-2022) ($MN)
116 RoW Active Pharmaceutical Ingredients Market Outlook, By Biosimilar (2013-2022) ($MN)
117 RoW Active Pharmaceutical Ingredients Market Outlook, By High potency active pharmaceutical ingredients(HPAPI) (2013-2022) ($MN)
118 RoW Active Pharmaceutical Ingredients Market Outlook, By Type of manufacturing (2013-2022) ($MN)
119 RoW Active Pharmaceutical Ingredients Market Outlook, By Captive (or in-house) manufacturing (2013-2022) ($MN)
120 RoW Active Pharmaceutical Ingredients Market Outlook, By Contract manufacturing (2013-2022) ($MN)
121 RoW Active Pharmaceutical Ingredients Market Outlook, By Therapeutic applications (2013-2022) ($MN)
122 RoW Active Pharmaceutical Ingredients Market Outlook, By Anti-Infectives (2013-2022) ($MN)
123 RoW Active Pharmaceutical Ingredients Market Outlook, By Cardiovascular and hematopoietic system (2013-2022) ($MN)
124 RoW Active Pharmaceutical Ingredients Market Outlook, By CNS and Neurological Disorders (2013-2022) ($MN)
125 RoW Active Pharmaceutical Ingredients Market Outlook, By Diabetes (2013-2022) ($MN)
126 RoW Active Pharmaceutical Ingredients Market Outlook, By Endocrinology (2013-2022) ($MN)
127 RoW Active Pharmaceutical Ingredients Market Outlook, By Gastrointestinal disorder (2013-2022) ($MN)
128 RoW Active Pharmaceutical Ingredients Market Outlook, By Hormonal-related disorder (2013-2022) ($MN)
129 RoW Active Pharmaceutical Ingredients Market Outlook, By Metabolic disorder (2013-2022) ($MN)
130 RoW Active Pharmaceutical Ingredients Market Outlook, By Musculoskeletal disorder (2013-2022) ($MN)
131 RoW Active Pharmaceutical Ingredients Market Outlook, By Nephrology (2013-2022) ($MN)
132 RoW Active Pharmaceutical Ingredients Market Outlook, By Oncology (2013-2022) ($MN)
133 RoW Active Pharmaceutical Ingredients Market Outlook, By Ophthalmology (2013-2022) ($MN)
134 RoW Active Pharmaceutical Ingredients Market Outlook, By Orthopedic Disorders (2013-2022) ($MN)
135 RoW Active Pharmaceutical Ingredients Market Outlook, By Pulmonology (2013-2022) ($MN)

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Bioniche Animal Health (Canada)
  • Boehringer Ingelheim (Germany)
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Limited
  • Bayer Healthcare (Germany)
  • Merial Inc. (Sanofi) (France)
  • Elanco Animal Health (U.S.)
  • Merck Animal Health (U.S.)
  • Ceva Animal Health, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Novartis International AG
  • Ranbaxy Laboratories
  • Virbac
  • Zoetis (U.S.)
  • Pfizer, Inc
  • Aurobindo Pharma Ltd.
  • Heska Co. (U.S.)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll